



For Immediate Release

Contact: Allison Potter
814.221.2661
allison@pascalecommunications.com
Pascale Communications, LLC

Michael Ford
707-256-2403
mford@santeninc.com
Santen Inc.

Santen Inc. Appoints Vice President of Clinical Affairs

NAPA, CA- May 28, 2010— Santen Inc., the U.S. subsidiary of global ophthalmic pharmaceutical company Santen Pharmaceutical Co., Ltd. (Osaka, Japan) announced the appointment of Naveed Shams, M.D., Ph.D as VP of Clinical Affairs. Dr. Shams' addition to Santen Inc. further strengthens their leadership and provides diversity given his extensive experience in the development of ophthalmic products.

"Dr. Shams is a highly respected scientist and brings an expertise in developing and commercializing ophthalmic drugs", said Santen Chief Operating Officer, Aki Tsujimura. "His insights in this area will prove invaluable, as he has a wealth of experience in basic research, drug discovery, ophthalmic formulations, and drug delivery."

In his 16 years of experience in global drug development, he has played a significant and critical role in bringing three products to market including, Zaditen®, Rescula®, and Lucentis®. He also supported the post-marketing efforts for Visudyne®. His industry experience spans companies such as Genentech, Novartis, Opko Health, Storz Ophthalmics, and most recently On Demand Therapeutics, a drug delivery start up in the San Francisco Bay area where he was President & Chief Medical Officer. While at Genentech, Dr. Shams led the clinical team in the development and approval of Ranibizumab (Lucentis®).

Yusuf Ali, Ph.D., Vice President of Research and Development, commented, "We are delighted that Naveed has joined Santen Inc. His extensive experience in global clinical research & development will be invaluable to Santen as we bring new and innovative products to the global market place to address unmet medical needs for our patients".

Dr. Shams received his medical degree from Dow Medical College in Karachi, Pakistan, and his Ph.D. from the University of South Carolina in microbiology and immunology. He completed fellowships in cornea and external diseases at Harvard Medical School and histocompatibility and immunogenetics at Massachusetts General Hospital. Dr. Shams was formerly on faculty at Schepens' Eye Research Institute and the Department of Ophthalmology at Harvard Medical School.

-more-

“As VP of Clinical Affairs, I look forward to aiding Santen in their initiative to bring innovative ophthalmic products to the company’s global products pipeline,” stated Dr. Shams. “My experience in drug development spans from the anterior segment through the posterior segment and will help strengthen the company in respect to their drug development.”

About Santen Inc.

Santen Inc., based in Napa, California, is the U.S. subsidiary of Santen Pharmaceutical Co., Ltd., a billion-dollar global company headquartered in Osaka, Japan since 1890. Santen researches, develops and markets ophthalmic products for physicians worldwide. Among prescription ophthalmic pharmaceuticals, Santen holds the top share within the Japanese and Chinese markets and is one of the leading ophthalmic companies worldwide. Santen has subsidiaries in the U.S., Europe and Asia, including its wholly-owned Napa, California-based Santen Inc. Santen’s global product pipeline includes many more prescription pharmaceuticals in varying clinical trial phases. A detailed listing, as well as additional corporate information, is available online at www.santeninc.com.

*Lucentis is a registered trademark of Genentech, Inc. Zaditor, Rescula and Visudyne are registered trademarks of Novartis Pharma

###